Here are the 10-K annual reports from Intellia Therapeutics, Inc (NTLA) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow NTLA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NTLA filings page.
Intellia Therapeutics is a genome-editing biotech developing in vivo CRISPR medicines, led by two Phase 3 programs. Lonvoguran ziclumeran (lonvo-z, NTLA-2002) targets hereditary angioedema with a one-time IV treatment; the HAELO Phase 3 trial fully enrolled 80 patients, with topline data expected by mid-2026 and a planned U.S. launch in the first half of 2027, following a BLA filing in the second half of 2026.
Nexiguran ziclumeran (nex-z, NTLA-2001) targets ATTR amyloidosis. The MAGNITUDE Phase 3 cardiomyopathy trial is on FDA clinical hold after a case of severe liver injury and a subsequent patient death, while the FDA has lifted the hold on the MAGNITUDE-2 Phase 3 polyneuropathy trial. Earlier Phase 1 data showed deep, durable TTR reductions and signs of disease stabilization. Intellia also advances additional CRISPR and cell-therapy collaborations, including a co-development deal with Regeneron and licensed ex vivo programs, and highlights extensive regulatory, manufacturing, competition and IP risks typical for first-wave CRISPR therapies.